Eiger Shifts Focus After Phase II Failure In PAH

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Finding no improvement with ubenimex in PAH, Eiger ends development but continues with the drug in lymphedema, plus hepatitis D and post-bariatric hypoglycemia candidates.

Businessman touched r and d sign. R d icon network business concept word cloud background tag. R&D: Research and development word lettering typography design illustration with line icons and ornaments

Rare disease-focused Eiger BioPharmaceuticals Inc. reached a quick decision on its Phase II candidate in pulmonary arterial hypertension after ubenimex failed to show a benefit in the primary or secondary endpoints in a Phase II study. The firm revealed Jan. 16 that it will cease development in that indication, while continuing a Phase II study with the same molecule in lymphedema.

Market analysts largely maintained a positive outlook, noting that PAH was not a major driver of the company's value. BTIG...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D